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Abstract
Background: The recent emergence of four new members of the paramyxovirus family has heightened
the awareness of and re-energized research on new and emerging diseases. In particular, the high mortality
and person to person transmission associated with the most recent Nipah virus outbreaks, as well as the
very recent re-emergence of Hendra virus, has confirmed the importance of developing effective
therapeutic interventions. We have previously shown that peptides corresponding to the C-terminal
heptad repeat (HR-2) of the fusion envelope glycoprotein of Hendra virus and Nipah virus were potent
inhibitors of both Hendra virus and Nipah virus-mediated membrane fusion using recombinant expression
systems. In the current study, we have developed shorter, second generation HR-2 peptides which include
a capped peptide via amidation and acetylation and two poly(ethylene glycol)-linked (PEGylated) peptides,
one with the PEG moity at the C-terminus and the other at the N-terminus. Here, we have evaluated these
peptides as well as the corresponding scrambled peptide controls in Nipah virus and Hendra virus-
mediated membrane fusion and against infection by live virus in vitro.
Results: Unlike their predecessors, the second generation HR-2 peptides exhibited high solubility and
improved synthesis yields. Importantly, both Nipah virus and Hendra virus-mediated fusion as well as live
virus infection were potently inhibited by both capped and PEGylated peptides with IC50 concentrations
similar to the original HR-2 peptides, whereas the scrambled modified peptides had no inhibitory effect.
These data also indicate that these chemical modifications did not alter the functional properties of the
peptides as inhibitors.
Conclusion: Nipah virus and Hendra virus infection in vitro can be potently blocked by specific HR-2
peptides. The improved synthesis and solubility characteristics of the second generation HR-2 peptides
will facilitate peptide synthesis for pre-clinical trial application in an animal model of Henipavirus infection.
The applied chemical modifications are also predicted to increase the serum half-life in vivo and should
increase the chance of success in the development of an effective antiviral therapy.
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Background
Two novel zoonotic paramyxoviruses have emerged to
cause disease in the past decade, Hendra virus (HeV) in
Australia in 1994–5 [1], and Nipah virus (NiV) in Malay-
sia in 1999 [2]. HeV and NiV caused severe respiratory and
encephalitic disease in animals and humans (reviewed in
[3,4]), HeV was transmitted to humans by close contact
with infected horses; NiV was passed from infected pigs to
humans. Both are unusual among the paramyxoviruses in
their ability to infect and cause potentially fatal disease in
a number of host species, including humans. Both viruses
also have an exceptionally large genome and are geneti-
cally closely related yet distinct from all other paramyxo-
virus family members. Due to their unique genetic and
biological properties, HeV and NiV have been classified as
prototypic members of the new genus Henipavirus, in the
family Paramyxoviridae [5,6]. Serological surveillance
and virus isolation studies indicated that HeV and NiV
reside naturally in flying foxes in the genus Pteropus
(reviewed in [7]). Investigation of possible mechanisms
precipitating their emergence indicates ecological changes
resulting from deforestation, human encroachment into
bat habitats and high intensity livestock farming practices
as the likely primary factors [7]. Because these viruses are
harboured in a mammalian reservoir whose range is vast,
both HeV and NiV have the capability to cause disease
over a large area and in new regions where disease was not
seen previously. There have been several other suspected
NiV occurrences since its recognition in 1999. Recently
two confirmed outbreaks in 2004 in Bangladesh caused
fatal encephalitis in humans and for the first time, person-
to-person transmission appeared to have been a primary
mode of spread [8-12]. In addition, there appeared to be
direct transmission of the virus from the flying fox to
humans, and the case mortality rate was ~70%; signifi-
cantly higher than any other NiV outbreak to date. Cur-
rently, HeV and NiV are categorized as biological safety
level-4 (BSL-4) pathogens, and NiV has also been classi-
fied as a category C priority pathogen. Category C agents
include emerging pathogens that could be engineered for
mass dissemination in the future because of availability;
ease of production and dissemination; and potential for
high morbidity and mortality and major health impact.
All of the above reasons illustrate why an effective antivi-
ral therapy is needed for henipaviruses.
Paramyxoviruses contain two membrane-anchored glyco-
proteins that are required for virion attachment to and
fusion with the membrane of the host cell. Depending on
the biological properties of the virus, the attachment pro-
tein is referred to as either the hemagglutinin-neuramini-
dase (HN), the hemagglutinin (H), or the G glycoprotein
which lacks hemagglutinating and neuraminidase activi-
ties. Whereas most paramyxoviruses employ sialic acid
moieties as receptors, HeV and NiV make use of a cell-sur-
face expressed protein and their G glycoprotein binds to
ephrin-B2 on host cells [13]. The fusion protein (F) facili-
tates the fusion of virion and host cell membranes during
virus infection, and is an oligomeric homotrimer [14,15].
The biologically active F protein consists of two disulfide
linked subunits, F1 and F2, which are generated by the pro-
teolytic cleavage of a precursor polypeptide known as F0
(reviewed in [16,17]). In all cases the membrane-
anchored subunit, F1, contains a new amino terminus that
is hydrophobic and highly conserved across virus families
and referred to as the fusion peptide (reviewed in [18]).
There have been considerable advances in the understand-
ing of the structural features and development of mecha-
nistic models of how several viral envelope glycoproteins
function in driving the membrane fusion reaction
(reviewed in [19-21]). One important feature of many of
these fusion glycoproteins are two α-helical domains
referred to as heptad repeats (HR) that are involved in the
formation of a trimer-of-hairpins structure [22,23]. HR-1
is located proximal to the amino (N)-terminal fusion pep-
tide and HR-2 precedes the transmembrane domain near
the carboxyl (C)-terminus [22,24-26]. For many viral
fusion glycoproteins the N-terminal HR-1 forms an inte-
rior, trimeric coiled-coil surrounded by three anti-parallel
helices formed from HR-2 (reviewed in [18]). Both the
HeV and NiV F glycoprotein HR domains have been
shown to interact with each other and form the typical 6-
helix coiled-coil bundles [24,27].
Peptide sequences from either HR domain of the F glyco-
protein of several paramyxoviruses, including HeV and
NiV have been shown to be inhibitors of fusion [25,28-
35]. Targeting this membrane fusion step of the viral
infection process has garnered much attention, primarily
lead by work on human immunodeficiency virus type 1
(HIV-1) (reviewed in [36]). Indeed, the HIV-1 envelope
derived peptide, enfuvirtide (Fuzeon™, formerly T-20),
has been clinically successful [37,38]. Enfuvirtide is a 36-
amino acid peptide corresponding to a portion of the C-
terminal HR-2 domain of the gp41 subunit of the enve-
lope glycoprotein. Approved by the FDA in March 2003,
enfuvirtide has been shown to be comparable to other
anti-retroviral therapeutics in terms of reducing viral load,
and is generally well tolerated despite its parenteral
administration, and enfuvirtide has added significantly to
optimized combination therapy in a growing number of
patients with multiple HIV-1 resistance to the currently
available antiretroviral drugs [39].
No therapeutic treatments are currently available for HeV
or NiV infection. In our previous studies, we demon-
strated that peptides derived from the HR-2 of either the
HeV or NiV F were potent inhibitors of fusion [34]. How-
ever, although these peptides were effective, their specific
properties such as overall length where not optimized,Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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and they were large and somewhat insoluble making syn-
thesis and purification problematic. In preparation to
evaluate these peptides as potential therapeutic fusion
inhibitors against NiV and HeV infection, second genera-
tion versions were designed with changes aimed at
improving their solubility and in vivo half-life when
administered to animals. In the current study, we have
produced shorter 36 amino acid capped peptides by ami-
dation at the N-terminus and acetylation at the carboxyl-
terminus. In addition, two alternate peptide versions were
made with the addition of a poly(ethylene glycol) moiety
to either the C-terminus or the N-terminus. Here we
report on the biological activity of these modified pep-
tides and demonstrate that chemical modification
increased solubility significantly without altering their
biological properties of inhibiting membrane fusion. Fur-
ther, all three versions were capable of blocking both
fusion as well as live HeV and NiV infection with IC50 con-
centrations in the nM range, similar to those reported
with other viral systems.
Results
Heptad peptide inhibition of Hendra virus and Nipah 
virus-mediated cell-cell fusion
Hypothetical models of the transmembrane (F1) glyco-
proteins of HeV and NiV are shown in Fig. 1. The models
are derived by homology modeling with the known struc-
ture of the F protein of Newcastle disease virus [40]. These
models are consistent protein structures predicted by the
computer algorithms PHDsec [41] and TMpred [42].
Overall, the structures of the HeV and NiV F1 transmem-
brane subunit, including the heptad repeats (HR-1 and
HR-2 helices), closely resemble that of the gp41 subunit
of the HIV-1 envelope glycoprotein [43-45]. The depicted
circle in the background represents the F2 subunit of NiV
F. Due to the structural similarities and clinical success of
the gp41 heptad peptides, we hypothesized that peptides
derived from the HR-2 of HeV or NiV F would be effective
antiviral therapies for henipavirus infection. In previous
studies we evaluated the inhibition properties of 42
amino acid length peptides derived from both the N and
C-terminal heptad repeats (HR-1 and HR-2) of HeV and
NiV F in a vaccinia virus-based reporter gene assay that
quantitatively measured cell-cell fusion mediated by the
envelope glycoproteins of HeV and NiV [25,34]. Although
both HR-1 and HR-2 derived peptides exhibited fusion
inhibitory activity, the HR-2 peptide (residues 447–489)
was more potent and more soluble. The HeV and NiV HR-
2 peptides differed at three locations (amino acids 450,
479 and 480) with phenylalanine, arginine and leucine in
NiV replaced by tyrosine, lysine and isoleucine in HeV
[6,46]. These differences in the sequence of either peptide
did not alter their homologous or heterologous inhibitory
activity, suggesting that either peptide possessed potential
therapeutic activity to both HeV and NiV. Here, we
designed second generation versions of the NiV based HR-
2 derived peptide with changes aimed at improving their
solubility and in vivo half-life when administered to ani-
mals. Shorter, 36 amino acid capped peptides were syn-
thesized (sequence denoted as FC2 in Fig. 1) by
amidation at the N-terminus and acetylation at the car-
boxyl-terminus, modifications known to have improved
in vivo half-life of Fuzeon™ (Thomas Matthews, Trimeris
Inc., personal communication). In addition, two alternate
peptide versions were made with the addition of a
poly(ethylene glycol) moiety to either the C-terminus or
the N-terminus which improved peptide solubility during
preparation, and may also potentially improve the phar-
macokinetics in vivo [47,48].
First, we examined the activity of the capped peptides on
HeV and NiV-mediated membrane fusion. In previous
studies, un-capped heptad-derived peptides had to be dis-
solved initially in 100% DMSO at concentrations between
50 and 500 µg/ml and then diluted in medium in order to
maintain solubility. Here, the capped heptad-derived pep-
tide (capped-NiV FC2) was completely soluble and dis-
solved in cell culture medium at concentrations as high as
10 mg/ml. For cell-cell fusion, envelope expressing-effec-
tor cells were added to peptides prior to the addition of
target cells. Shown in Fig. 2 are the dose-dependent inhi-
bition profiles of HeV (column one) and NiV-mediated
(column 2) cell-cell fusion mediated by the capped-NiV
FC2 peptide in Vero (Fig. 2A), U373 (Fig. 2B), and PCI 13
(Fig. 2C) cell lines. The scrambled, capped, control pep-
tide (capped-ScNiV FC2) had no inhibitory effect, over
the same concentration range, on the cell-fusion mediated
by either virus in any of the three cell lines. NiV-mediated
fusion appeared to be slightly more sensitive to peptide
inhibition in comparison to the cell-fusion activity of
HeV, although the calculated IC50 concentrations in each
were comparable (Table 1). Importantly, the IC50 values
of the capped version of NiV FC2 in these in vitro cell-cell
fusion assays were within the 13–27 nM range, similar to
what was observed in prior studies utilizing un-capped
versions of the 42 amino acid heptad-derived peptides
which yielded IC50 values between 5.2 and 5.8 nM [34].
Using the cell-cell fusion assay we next examined the PEG-
modified versions of NiV FC2. As predicted, these
pegylated heptad peptides also possessed increased solu-
bility characteristics and could be readily prepared at con-
centrations up to 10 mg/ml. The dose-response inhibition
results of the N-PEG-NiV FC2 and C-PEG-NiV FC2 pep-
tides are shown in Fig. 3, and inhibition was demon-
strated in Vero (Fig. 3A), U373 (Fig. 3B), and PCI 13 (Fig.
3C) cell lines. Both pegylated versions of NiV FC2 were
capable of blocking NiV and HeV-mediated cell-fusion,
while the scrambled PEG-control peptide (C-PEG-ScNiV
FC2) had no inhibitory activity. Because of the requiredVirology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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specificity of the heptad peptide amino acid sequence to
convey fusion inhibitory activity, as well as the high cost
of peptide synthesis, we chose to only synthesize one ver-
sion of the scrambled peptide as a pegylated control with
the PEG10 moiety linked to the C-terminus. It was also
noted that the NiV FC2 peptide with the PEG10 moiety
Hypothetical models of the transmembrane (F1) glycoproteins of Hendra virus and Nipah virus Figure 1
Hypothetical models of the transmembrane (F1) glycoproteins of Hendra virus and Nipah virus. The models are 
derived by homology modeling with the known structure of the F protein of Newcastle disease virus [40]. These models are 
consistent protein structures predicted by the computer algorithms PHDsec [41] and TMpred [42] as described in the Meth-
ods. The heptad repeats are indicated as HR-1 (grey) and HR-2 (yellow/orange), transmembrane anchor (blue). The F2 subunit 
is represented by the circle behind the F1 subunit. The 36 amino acid fusion inhibitor peptide sequence used in the present 
study is designated as FC2 and is boxed (yellow). The equivalent location of FC2 in the HeV F1 subunit is shown for 
comparison.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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Inhibition of Hendra virus and Nipah virus-mediated cell-cell fusion by capped C-terminal heptad peptide NiV FC2 Figure 2
Inhibition of Hendra virus and Nipah virus-mediated cell-cell fusion by capped C-terminal heptad peptide NiV 
FC2. HeLa cells were infected with vaccinia recombinants encoding HeV F and HeV G or NiV F and NiV G glycoproteins, 
along with a vaccinia recombinant encoding T7 RNA polymerase (effector cells). Each designated target cell type was infected 
with the E. coli LacZ-encoding reporter vaccinia virus vCB21R. Each target cell type (1 × 105) was plated in duplicate wells of a 
96-well plate. Inhibition was carried out using either capped NiV FC2 or ScNiV FC2 (control) heptad peptide. Peptides were 
added to the HeV or NiV glycoprotein-expressing cells (1 × 105), incubated for 30 min at 37°C, and then each target cell type 
was added. The cell fusion assay was performed for 2.5 hr at 37°C, followed by lysis in Nonidet P-40 (1%) and β-Gal activity 
was quantified.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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added to the C-terminus had significantly reduced inhib-
itory capacity, as compared to PEG10 added to the N-ter-
minus, against both NiV and HeV-mediated cell-fusion in
all three cell lines tested. The reduction of C-PEG-NiV FC2
activity versus N-PEG-NiV FC2 was approximately 20-fold
in all cases (Table 1) with the exception of HeV-mediated
cell-fusion with the U373 cell line (Fig. 3B). Importantly,
in all cases, the N-PEG-NiV FC2 demonstrated very simi-
lar IC50s (3–10 nM) to what was observed in prior studies
utilizing un-capped versions of the 42 amino acid heptad-
derived peptides (5–6 nM).
Heptad peptide inhibition of Hendra virus and Nipah virus 
infection
We next sought to confirm the inhibitory activity of Nipah
virus heptad-derived peptides on the infection of live HeV
and NiV in cell culture. We routinely employ Vero cell cul-
ture to perform live henipavirus infection assays, as well
as in the propagation of virus stocks. The infection of Vero
cells with HeV or NiV produced characteristic syncytial
morphologies for each virus [49]. HeV reproducibly incor-
porated surrounding cells in the culture monolayer into
each syncytium with the cell nuclei and viral proteins
spread throughout the majority of the giant cell. In con-
trast, NiV infected syncytia initially demonstrated a simi-
lar appearance to their HeV counterparts, but
characteristically both cell nuclei and viral protein were
later sequestered around the periphery of each giant cell
leaving the central region largely empty. In order to assess
the extent of viral infection, we have developed an assay
that will detect viral protein by immunofluorescence
staining and localization of the P protein using a cross-
reactive anti-P peptide-specific antiserum. Using this syn-
cytia-based immunofluorescence infection assay, we ini-
tially tested the N-PEG NiV FC2 peptide for its ability to
block virus infection and results are shown in Fig. 4. In the
absence of peptide, the different syncytial morphologies
of HeV and NiV- infected cells were clearly evident. In the
HeV-infected syncytia (Fig. 4A), the viral P protein was
spread throughout the majority of the giant cell; whereas,
the NiV-infected syncytia (Fig. 4D) were circular structures
delineated by a ring of the viral antigen. Incubation of 500
nM N-PEG-NiV FC2 with either HeV (Fig. 4B) or NiV (Fig.
4E) infected cells resulted in a dramatic and robust reduc-
tion in syncytial size although the number of syncytia per
cell monolayer remained largely unchanged. In parallel,
the incubation of 500 nM C-PEG-ScNiV FC2 control pep-
tide with HeV or NiV-infected cells (Fig. 4C and 4F respec-
tively) revealed a syncytial morphology and size identical
to those observed in the absence of any peptide.
We next used the syncytia-based immunofluorescence
infection assay to examine all of the peptides over a range
of concentrations in two different cell lines. We further
preformed a quantitative analysis of syncytial areas based
on immunofluorescence detection of viral antigen for
HeV and NiV (see Materials and Methods) and revealed a
grading of syncytial area inversely proportional to peptide
concentration. Shown in Fig. 5 is the quantitative analysis
of the syncytial area observed in HeV and NiV infection of
both Vero (Fig. 5A and 5B) and PCI 13 (Fig. 5C and 5D)
cell cultures over a range of concentrations of the capped-
NiV FC2 peptide. In all cases significant inhibition of HeV
and NiV infection and spread is observed in comparison
to the scrambled capped control peptide (capped-ScNiV
FC2). Similarly, shown in Fig. 6, both the N-PEG and C-
PEG NiV FC2 peptides possessed potent inhibitory activ-
ity on HeV and NiV infection in Vero (Fig. 6A and 6B) and
PCI 13 (Fig. 6C and 6D) cell cultures. Again, the scram-
bled C-PEG control peptide (C-PEG-ScNiV FC2) had no
effect at any concentration tested. As was observed in the
cell-cell fusion assays, in all cases, the C-PEG-NiV FC2
peptide exhibited weaker inhibitory activity in blocking
virus infection, spread and syncytial size in comparison to
Table 1: Summary of 50% inhibitory concentration values of peptide fusion inhibitors in cell-cell fusion and virus infection assays.
Virus Cell line IC50* Capped NiV FC2 (nM) IC50 N-PEG NiV FC2 (nM) IC50 C-PEG NiV FC2 (nM)
Fusion Inhibition HeV Vero 17.59 6.54 142.4
NiV Vero 13.08 3.66 98.05
HeV U373 23.91 9.71 78.07
NiV U373 16.28 4.85 79.19
HeV PCI 13 27.54 6.18 147.2
NiV PCI 13 17.79 5.04 93.32
Live virus Inhibition HeV Vero 4.17 0.46 14.28
NiV Vero 11.42 1.36 43.76
HeV PCI 13 53.51 2.05 11.94
NiV PCI 13 2.70 1.26 55.57
*All IC50s were calculated using the non-linear regression function of GraphPad Prism software.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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Inhibition of Hendra virus and Nipah virus-mediated cell-cell fusion by N-terminal and C-terminal (PEG10) pegylated heptad  peptide NiV FC2 Figure 3
Inhibition of Hendra virus and Nipah virus-mediated cell-cell fusion by N-terminal and C-terminal (PEG10) 
pegylated heptad peptide NiV FC2. HeLa cells were infected with vaccinia recombinants encoding HeV F and HeV G or 
NiV F and NiV G glycoproteins, along with a vaccinia recombinant encoding T7 RNA polymerase (effector cells). Each desig-
nated target cell type was infected with the E. coli LacZ-encoding reporter vaccinia virus vCB21R. Each target cell type (1 × 105) 
was plated in duplicate wells of a 96-well plate. Inhibition was carried out using either the N-terminal (N-PEG-NiV FC2) or C-
terminal (C-PEG-NiV FC2) pegylated and capped heptad peptides or C-terminal pegylated scrambled control peptide (C-PEG-
ScNiV FC2). Peptides were added to the HeV or NiV glycoprotein-expressing cells (1 × 105), incubated for 30 min at 37°C, 
and then each target cell type was added The cell fusion assay was performed for 2.5 hr at 37°C, followed by lysis in Nonidet 
P-40 (1%) and β-Gal activity was quantified.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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Immunofluorescence-based syncytia assay of Hendra virus and Nipah virus infection Figure 4
Immunofluorescence-based syncytia assay of Hendra virus and Nipah virus infection. Vero cells were plated into 
96 well plates and grown to 90% confluence. Cells were pre-treated with heptad peptides for 30 min at 37°C prior to infection 
with 1.5 × 103 TCID50/ml and 7.5 × 102 TCID50/ml of live HeV or NiV (combined with peptide). Cells were incubated for 24 
hours, fixed in methanol and immunofluorescently stained for P protein prior to digital microscopy. Images were obtained 
using an Olympus IX71 inverted microscope coupled to an Olympus DP70 high resolution color camera and all images were 
obtained at an original magnification of 85×. Representative images of FITC immunofluorescence of anti-P labeled HeV and NiV 
syncytia are shown. A: HeV without peptide. B: HeV with C-PEG-NiV FC2. C: HeV with N-PEG-ScNiV FC2. D: NiV without 
peptide. E: NiV with N-PEG-NiV FC2. F: NiV with N-PEG-ScNiV FC2.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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the N-PEG-NiV FC2. The N-PEG-NiV FC2 peptide had
considerable potency against both NiV and HeV and the
calculated IC50 values for inhibiting either virus on both
cell lines ranged from 0.46 nM to 2.05 nM (Table 1).
Discussion
Both NiV and HeV continue to re-emerge, and in early
2004 two NiV outbreaks in Bangladesh have been con-
firmed totalling some 53 human cases of infection, and
HeV has reappeared in Northern Australia in late 2004
with two cases of fatal infection in horses and one non-
fatal human case [50]. The most recent NiV occurrence
has again appeared in Bangladesh in January of 2005 [51].
Several important observations in these most recent out-
breaks of NiV have been made, including a higher inci-
dence of acute respiratory distress syndrome, person-to-
person transmission occurring in the majority of cases,
and significantly higher case fatality rates (60–75%), and
no direct link to infected livestock or domestic animals [8-
12,51]. In particular, the availability of NiV in the
Inhibition of Hendra virus and Nipah virus infection by capped heptad peptides Figure 5
Inhibition of Hendra virus and Nipah virus infection by capped heptad peptides. Vero cells or PCI 13 cells were 
plated into 96 well plates and grown to 90% confluence. Cells were pre-treated with the indicated peptide for 30 min at 37°C 
prior to infection with 1.5 × 103 TCID50/ml and 7.5 × 102 TCID50/ml of live HeV or NiV (combined with peptide). Cells were 
incubated for 24 hours, fixed in methanol and immunofluorescently labeled for P protein prior to digital microscopy and image 
analysis to determine the relative area of each syncytium (see Methods). The figure shows the relative syncytial area (pixel2) 
versus the indicated peptide concentration for HeV and NiV.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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environment and the ability to grow the virus to high titer
in the laboratory, it is also now considered a potential bio-
logical terror agent. Taken together these observations
highlight the need to explore therapeutic strategies for
henipaviruses. While there is some evidence that ribavirin
therapy may be of clinical benefit [52], there are currently
no other specific treatment options and only supportive
care is indicated.
Paramyxoviruses, like retroviruses, possess a class I mem-
brane fusion mechanism, and there have been major
recent advances in the understanding of the structural
requirements and mechanisms involved in the fusion
process mediated by these viruses (reviewed in [19,53-
55]). The present model of class I membrane fusion
describes the formation of a trimer-of-hairpins structure
whose oligomeric coiled-coil formation is mediated by
the 2 α-helical heptad repeat domains of the fusion glyc-
oprotein which drives membrane fusion. Peptides
Inhibition of Hendra virus and Nipah virus infection by N-terminal and C-terminal pegylated heptad peptides Figure 6
Inhibition of Hendra virus and Nipah virus infection by N-terminal and C-terminal pegylated heptad peptides. 
Vero cells or PCI 13 cells were plated into 96 well plates and grown to 90% confluence. Cells were pre-treated with the indi-
cated peptide for 30 min at 37°C prior to infection with 1.5 × 103 TCID50/ml and 7.5 × 102 TCID50/ml of live HeV or NiV 
(combined with peptide). Cells were incubated for 24 hours, fixed in methanol and immunofluorescently labeled for P protein 
prior to digital microscopy and image analysis to determine the relative area of each syncytium (see Methods). The figure 
shows the relative syncytial area (pixel2) versus the indicated peptide concentration for HeV and NiV.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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corresponding to either of these heptad domains block
fusion by interfering with the formation of the trimer-of-
hairpins structure, first noted with sequences derived
from the gp41 subunit of the HIV-1 envelope glycoprotein
[56,57]. HIV-1 heptad-peptides have now met with clini-
cal success and are the first approved fusion inhibitor ther-
apeutics for a viral infection. Peptide sequences from
either the N or C heptads of the F glycoprotein from a vari-
ety of paramyxoviruses have also been shown to inhibit
fusion [28-33,58]. Previously, we demonstrated that
fusion-inhibiting peptides corresponding to the C-termi-
nal heptad repeat domain of the F glycoprotein of either
HeV or NiV could potently inhibit the membrane fusion
activity of either virus [25,34]. Because the peptides
derived from the HR-2 of NiV F could inhibit both HeV
and NiV-mediated fusion, in this study we only pursued
peptides derived from NiV F. Furthermore, we have
refined our initial peptide fusion inhibitors by reducing
their length and chemically modifying their amino and
carboxyl termini either by amidation or acetylation or
through the addition of a PEG10 moiety, and have exam-
ined these new peptides in both membrane fusion and
virus infection assays.
We have demonstrated that Henipavirus-mediated fusion
and infection can be potently inhibited by these chemi-
cally modified peptides in vitro in a dose-dependent fash-
ion. Overall, the IC50 concentrations of the peptides in the
present study were similar to our previous observations
on un-capped 42-mer peptides against HeV and NiV-
mediated cell-cell fusion as well as to those observed in
other paramyxovirus and retrovirus systems. However, we
found that the N-terminal pegylated NiV FC2 peptide
used here to be particularly potent with overall IC50 values
of <10 nM for both HeV and NiV cell-cell fusion and virus
infection. The present results indicate that both the
capped and pegylated peptides are equally as effective as
the unmodified first generation fusion-inhibiting pep-
tides. Interestingly, peptides with the PEG10 moiety linked
to the C-terminus were slightly, yet reproducibly, less
effective than N-terminal pegylated peptides. We specu-
late that this could reflect some process of steric hindrance
effect by the PEG10  moiety in interacting with the F
glycoprotein during its conformational alteration leading
to 6-helix bundle formation.
These same chemical modifications also improved the
solubility characteristics of the heptad-derived peptides,
and also significantly increased the yield during synthesis
and purification (data not shown). The primary objectives
of the present study were to demonstrate that these
peptides possessed potent inhibitory activity in surrogate
viral glycoprotein-mediated membrane fusion assays as
well as in live virus infection assays, and improve peptide
solubility and synthesis yields. The specific chemical
modifications were chosen, especially pegylation, to help
improve the plasma half-life and thus enhance
therapeutic success. Covalent coupling of PEG to proteins
or "pegylation" is currently considered one of the most
successful techniques to prolong the residence time of
protein drugs in the bloodstream [47,59-61]. PEG is a
water soluble polymer that when covalently linked to
molecules, conveys its physico-chemical properties and
therefore modifies the biodistribution and solubility of
peptide and non-peptide drugs. Additionally, pegylation
masks the peptide's surface and increases the molecular
size of the polypeptide, thus reducing its renal ultrafiltra-
tion. PEG modification can also prevent the approach of
antibodies or antigen processing cells and reduce their
degradation by proteolytic enzymes [62].
Conclusion
The isolation of four new members of the family Para-
myxoviridae  in the past 10 years in addition to several
largely uncharacterised paramyxoviruses recovered from
historical rodent and snake sampling may indicate a
much larger than previously thought, reservoir of para-
myxoviruses. Given the success of heptad-derived peptide
inhibition of paramyxovirus fusion, many of these new
and yet to be discovered viruses may well be inherently
treatable, such that the possibility of antiviral therapy may
be available as soon as a sequence has been obtained for
the respective fusion envelope glycoprotein. We are pres-
ently evaluating the properties of these anti-HeV and NiV
fusion inhibiting peptides as well as their potential thera-
peutic value with an in vivo model of virus infection.
Methods
Cells and Culture conditions
HeLa cells (ATCC CCL 2) and African green monkey
(Vero) cells (ATCC CCL 81) were obtained from the
American Type Culture Collection. A HeLa cell line deriv-
ative (HeLa-USU) which does not express the NiV and
HeV receptor, ephrin-B2 [13] was provided by Anthony
Maurelli, USUHS, Bethesda, MD. The human glioblast-
oma cell line U373-MG was provided by Adam P. Geballe,
Fred Hutchinson Cancer Research Center, Seattle, WA
[63]. The human head and neck carcinoma PCI 13 cell
line was the kind gift of Ernest Smith, Vaccinex, Inc. HeLa
and U373 cell monolayers were maintained in Dulbecco's
modified Eagle's medium supplemented with 10%
cosmic calf serum (CCS) (Hyclone, Logan, UT) and 2 mM
L-glutamine (DMEM-10). PCI 13 cell monolayers were
maintained in DMEM-10 supplemented with 1 mM
HEPES. Vero cells were maintained in the absence of anti-
biotics in Minimal Essential Medium containing Earle's
salts and 10% fetal calf serum (EMEM-10). All cell cul-
tures were maintained at 37°C under a humidified 5%
CO2 atmosphere.Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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Viruses
For expression of recombinant HeV and NiV F and G glyc-
oproteins, the following recombinant vaccinia viruses
were employed: vKB7 (NiV F), vKB6 (NiV G), vKB1 (HeV
F), vKB2 (HeV G) [25,34,64]. Bacteriophage T7 RNA
polymerase was produced by infection with vTF7-3 which
contains the T7 RNA polymerase gene linked to a vaccinia
virus promoter [65]. The E. coli lacZ gene linked to the T7
promoter was introduced into cells by infection with vac-
cinia virus recombinant vCB21R-LacZ, which was
described previously [66]. HeV stock virus (titer 1 × 108
TCID50/ml) was prepared as described [67]. NiV stock
virus (titer 3 × 107 TCID50/ml) was prepared as described
[68].
Cell-fusion assays
Fusion between envelope glycoprotein-expressing and tar-
get cells was measured by a reporter gene assay in which
the cytoplasm of one cell population contained vaccinia
virus-encoded T7 RNA polymerase and the cytoplasm of
the other contained the E. coli lacZ gene linked to the T7
promoter; β-galactosidase (β-Gal) is synthesized only in
fused cells [35,69]. Vaccinia virus-encoded proteins were
produced by infecting cells (moi = 10) and incubating
infected cells at 31°C overnight. Cell-fusion reactions
were conducted with the various cell mixtures in 96-well
plates at 37°C. Typically, the ratio of envelope glycopro-
tein-expressing cells to target cells was 1:1 (2 × 105 total
cells per well, 0.2-ml total volume). Cytosine arabinoside
(40 µg/ml) was added to the fusion reaction mixture to
reduce non-specific β-Gal production [35]. For quantita-
tive analyses, Nonidet P-40 was added (0.5% final) at 2.5
h and aliquots of the lysates were assayed for β-Gal at
ambient temperature with the substrate chlorophenol
red-D-galactopyranoside (CPRG; Roche Diagnostics
Corp.). For inhibition by peptides, serial dilutions of pep-
tides were performed and added to effector cell popula-
tions prior to the addition of target cell populations. All
assays were performed in duplicate and fusion results
were calculated and expressed as rates of β-Gal activity
(change in optical density at 570 nm per minute × 1,000).
Virus infection assay and immunofluorescence
Vero cells were seeded into 96 well plates at 6 × 104 cells/
300  µl and grown to 90% confluence in EMEM-10 at
37°C under a humidified 5% CO2 atmosphere. Peptides
were diluted 4-fold in EMEM. Under biohazard level 4
conditions, media were discarded and 100 µl of diluted
virus was added to each well and incubated at 37°C for 30
min. Virus dilutions were chosen to generate 50 plaques
under these adsorption conditions. Virus inoculum was
removed and 200 µl of diluted peptide was added to each
well and incubated at 37°C for 18 h. The culture medium
was discarded and plates were immersed in ice-cold abso-
lute methanol for at least 20 min prior to air-drying out-
side the biohazard level 4 facility. Fixed plates were
immunolabeled with anti-P monospecific antisera [70].
Briefly, slides were washed in 0.01 M phosphate-buffered
saline (PBS), pH 7.2 containing 1% BSA for 5 min. 40 µl
of anti-P antiserum (1:200 in PBS-BSA) was applied to
each well and incubated at 37°C for 30 min. Slides were
rinsed with PBS containing 0.05% Tween 20 (PBS-T) and
washed for 5 min in PBS-BSA. 40 µl of FITC labeled goat
anti-rabbit antiserum (ICN Pharmaceuticals, Costa Mesa,
USA) diluted 1:100 in PBS-BSA was then applied to each
well and incubated at 37°C for 30 min. Slides were rinsed
again with PBS containing 0.05% Tween 20 (PBS-T) and
washed for 5 min in PBS-BSA. Wells were overlaid with
glycerol/PBS (1:1) containing DABCO (25 ug/ml) and
stored in the dark prior to imaging.
FITC immunofluorescence was visualized using an Olym-
pus IX71 inverted microscope (Olympus Australia, Mt.
Waverley, Australia) coupled to an Olympus DP70 high
resolution color camera. Image analysis was performed
using AnalySIS® image analysis software (Soft Imaging
System GmbH, Munster, Germany). Briefly, individual
virus syncytia were detected by threshold analysis fol-
lowed by "hole filling" and subsequently measured to
determine the area of each syncytium. To ensure repeata-
bility between images, all procedures were performed as a
macro function with fixed parameters. Nine images were
analysed for each peptide concentration resulting in the
collation of syncytial area data for between 9–36 foci per
peptide concentration (average ~15). Measurements were
collated and non-linear regression analysis performed
using GraphPad Prism software (GraphPad Software, San
Diego, CA USA) to determine the IC50.
Peptide synthesis
The following peptide sequence, corresponding to the C-
terminal α-helical heptad repeat domain (HR-2) of the
NiV F glycoprotein, was chosen for synthesis: KVDISS-
QISSMNQSLQQSKDYIKEAQRLLDTVNPSL (NiV FC2). A
scrambled version of the 36-amino-acid peptide was also
synthesized for use as a negative control KQSSMIS-
LQSQKSINSLPSQIRDYVQKTVLLAEDND (ScNiV FC2).
All peptides were synthesized utilizing the Fmoc/tBu pro-
tection scheme. The peptides with PEG(10) on the N-ter-
minus were synthesized on a PS3 automated synthesizer
(Protein Technologies Inc., Tucson, AZ) using NovaSYN®
TGR Resin (Nova Biochem, EMD Biosciences, Inc. La
Jolla, CA). The peptides with PEG(10) on the C-terminus
were synthesized on an ABI433 automated synthesizer
(Applied Biosystems, Foster City, CA) using 2-Chlorotrityl
resin (Nova Biochem). The protected amino acids were
incorporated into the peptide via active ester formation
using 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU)Virology Journal 2005, 2:57 http://www.virologyj.com/content/2/1/57
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(Nova Biochem). All Fmoc protected amino acids were
supplied by Nova Biochem. The protecting groups used
were as follows: sidechains of Asn, Cys, His, and Gln were
protected with Trityl (trt), Glu and Ser were protected with
tert-Butyl (tBu), Lys was protected with tert-Butyloxycarb-
onyl (Boc),Arg was protected with 2,2,4,6,7-pentamethyl-
dihydrobenzopfuran-5-sulfonyl (Pbf). Ala, Leu, Phe, Val,
and Gly were used without sidechain protection. PEG(10)
was incorporated using O-(N-Fmoc-2-aminoethyl)-O'-(2-
carboxyethyl)-undecaethyleneglycol (Nova Biochem) and
the peptides were acetylated by treatment with acetic
anhydride (Sigma-Aldrich). Peptides were cleaved from
the solid support using 92% trifluoacetic acid (Halocar-
bon), 2% anisole, 2% ethanedithiol, 2% triisopropylsi-
lane (all Sigma-Aldrich), and 2% water. Peptides were
purified on a Waters 600e semi-prep HPLC system using a
grace Vydac 300. Diphenyl column and solvents
0.1%TFA/water (A) and 0.1%TFA/acetonitrile (ACN) (B).
Analytical HPLC analysis of all fractions was performed
using a Waters Alliance 2695 with a 2.1 × 30 mm Symme-
try Shield™ RP18 3.5 m column. Matrix assisted laser des-
orption/ionization time of flight (MALDI-ToF) mass spec
analysis of the crude and pure peptides was performed
using an ABI Voyager DE Pro system. Crude peptide from
each synthesis and pure peptide was dissolved in
50%ACN/water and spotted with α-Cyano-4-Hydroxycin-
nimic Acid matrix (Sigma-Aldrich). Positive ions were
detected using the linear detector, which is calibrated with
Bradykinin and Angiotensin standards.
Proteomics computational methods
Methods to derive general models of surface glycoproteins
have been described previously [43]. Homology model-
ling of Hendra virus and Nipah virus F was based on the
structure of the F protein of Newcastle disease virus,
another member of the Paramyxoviridae, determined by
x-ray crystallography [40]. MacMolly (Soft Gene GmbH,
Berlin) was used to locate areas of sequence similarity and
to perform alignments. PHDsec (Columbia University
Bioinformatics Center, http://cubic.bioc.columbia.edu/
predictprotein/) was used for secondary structure predic-
tion [41]. PHDsec predicts secondary structure from mul-
tiple sequence alignments by a system of neural networks,
and is rated at an expected average accuracy of 72% for
three states, helix, strand and loop. Domains with signifi-
cant propensity to form transmembrane helices were
identified with TMpred (ExPASy, Swiss Institute of Bioin-
formatics, http://www.ch.embnet.org/software/
TMPRED_form.html). TMpred is based on a statistical
analysis of TMbase, a database of naturally occurring
transmembrane glycoproteins [42].
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